freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-10. Anything still debated is marked as such rather than presented as settled.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
== Co-polymers == Ordinary (homopolymeric) polystyrene has an excellent property profile about transparency, surface quality and stiffness. Its range of applications is further extended by copolymerization and other modifications (blends e.g. with PC and syndiotactic polystyrene). Several copolymers are used based on styrene: The brittleness of homopolymeric polystyrene is overcome by elastomer-modified styrene-butadiene copolymers. Copolymers of styrene and acrylonitrile (SAN) are more resistant to thermal stress, heat and chemicals than homopolymers and are also transparent. Copolymers called ABS have similar properties and can be used at low temperatures, but they are opaque.
==== Elimination ==== Pregabalin is eliminated by the kidneys in the urine, mainly in its unchanged form. It has a relatively short elimination half-life, with a reported value of 6.3 hours. Because of its short elimination half-life, pregabalin is administered 2 to 3 times per day to maintain therapeutic levels. The kidney clearance of pregabalin is 73 mL/minute. As pregabalin clearance is directly proportional to creatinine clearance, renal impairment leads to drug accumulation and elevated plasma concentrations. Dose adjustment is therefore required in patients with a creatinine clearance below 60 mL/min, with progressively greater reductions recommended as renal function declines. Patients undergoing hemodialysis require supplemental dosing following each session, as a standard four-hour treatment reduces plasma pregabalin concentrations by approximately 50%.
== Mechanism of action == Pholcodine is readily absorbed from the gastrointestinal tract and freely crosses the blood–brain barrier. It acts primarily on the central nervous system (CNS), causing depression of the cough reflex, partly by a direct effect on the cough centre in the medulla. It is metabolized in the liver and its action may be prolonged in individuals with hepatic insufficiency (i.e. liver problems). Its use is therefore contraindicated in patients with liver disease, while care is advised in patients with hepatic impairment.
Although MASLD can cause cirrhosis, liver failure, and liver cancer, most deaths among people with MASLD are attributable to cardiovascular disease. According to a meta-analysis of 34,000 people with MASLD over seven years, these individuals have a 65% increased risk of developing fatal or nonfatal cardiovascular events when compared to those without MASLD. MASLD and MASH increase the risk of liver cancer. Cirrhosis and liver cancer induced by MASLD or MASH were the second cause of liver transplantation in the US in 2017, with MASLD or MASH expected to overtake alcohol related liver disease as the most common indication for a liver transplantation in the future. People with MASH cirrhosis have an increased risk of liver cancer. The rate of liver cancer associated with MASH increased fourfold between 2002 and 2012 in the US, which is more than any other cause of liver cancer. MASLD constitutes the third most common risk factor for liver cancer. Cirrhosis is found in only about 50% of people with MASLD and with liver cancer, so liver cancer may occur without cirrhosis being present. MASLD and MASH also increase the risk of non-liver cancers, especially cancers of the gastrointestinal tract such as colon cancer. MASLD is a precursor of metabolic syndrome, although a bidirectional influence is possible. The presence and stage of fibrosis are the strongest prognostic factors for liver-related events and mortality, in particular for MASLD.
Sources: en.wikipedia.org
=== Bab–Bar === Stephen Moulton Babcock (1843–1931), American agricultural chemist worked on the "single-grain experiment" Myrtle Bachelder (1908–1997), American chemist noted for work on the Manhattan Project atomic bomb, and for work on metal chemistry Werner Emmanuel Bachmann (1901–1951), American chemist, known for work in steroids and RDX Simone Badal-McCreath (21st century), Jamaican chemist who created prostate and breast cancer cell lines Leo Baekeland (1863–1944), Belgian-American chemist known for invention of bakelite Adolf von Baeyer (1835–1917), German chemist, 1905 Nobel Prize in Chemistry, synthesis of indigo Piero Baglioni (born 1952), Italian chemist known for inorganic and organic colloids Hendrik Willem Bakhuis Roozeboom (1854–1907), Dutch chemist who studied phase behaviour in physical chemistry Alice Ball (1892–1916), American chemist known for inventing an effective injectable treatment for leprosy Emily Balskus (born 1980), American chemist and microbiologist known for work on the human microbiome Zhenan Bao (born 1970), Chinese chemist known for developing technologies with organic field-effect transistors and organic semiconductors Phil S. Baran (born 1977), American chemist known for synthesis, novel reactions and reagents Coral Barbas (PhD 1989), Spanish chemist known for research on metabolomics and integration of chemical data Allen J.
Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to encourage healthy behaviors that can decrease the negative consequences for those facing life challenges like homelessness and food insecurity, or engaging in harm-prone behaviors such as recreational drug use and sexual activity. Harm reduction initiatives recognize that people can make positive changes to protect themselves and others, without requiring abstinence. Harm reduction is most commonly applied to approaches that reduce adverse consequences from drug use, and harm reduction programs now operate across a range of services and in different regions of the world. As of 2020, some 86 countries had one or more programs using a harm reduction approach to substance use, primarily aimed at reducing blood-borne infections resulting from use of contaminated injecting equipment. Needle-exchange programmes, or syringe service programmes, reduce the likelihood of people who use heroin and other substances sharing the syringes and using them more than once. Syringe-sharing often leads to the spread of infections such as HIV or hepatitis C, which can easily spread from person to person through the reuse of syringes contaminated with infected blood. Needle and syringe programmes (NSP) and Opioid Agonist Therapy (OAT) outlets in some settings offer basic primary health care.
== Distribution and habitat == Sun anemones are marine organisms that are distributed in shallow areas of the sea floor, typically at depths from 1–10 m. This species is epibenthic. Commonly called the Caribbean Sun Anemone, S. helianthus are predominantly found in the Caribbean and Western Atlantic Seas. Additionally, they have been discovered along the coast of the United States, Canada, Costa Rica and Belize. S. helianthus may live singularly, but commonly live in dense aggregations such as in reef formations.
Sources: en.wikipedia.org
MCln·xH2O + x SOCl2 → MCln + x SO2 + 2x HCl If an excess of SOCl2 is used to dehydrate aluminium trichloride, it will form an adduct (1 molecule of thionyl chloride for each molecule of the aluminium trichloride dimer).
=== Translation start sites === Using a method developed by Hunt, Shine and Dalgarno showed that the nucleotide tract at the 3' end of E. coli 16S ribosomal RNA (rRNA) (that is, the end where translation begins) is pyrimidine-rich and has the specific sequence 5'-YACCUCCUUA-3'. They proposed that these ribosomal nucleotides recognize the complementary purine-rich sequence 5'-AGGAGGU-3', which is found upstream of the start codon AUG in a number of mRNAs found in viruses that affect E. coli. Many studies have confirmed that base pairing between the Shine–Dalgarno sequence in mRNA and the 3' end of 16S rRNA is of prime importance for initiation of translation by bacterial ribosomes. Given the complementary relationship between rRNA and the Shine–Dalgarno sequence in mRNA, it was proposed that the sequence at the 3'-end of the rRNA determines the capacity of the prokaryotic ribosome to translate a particular gene in an mRNA. Base pairing between the 3'-end of the rRNA and the Shine–Dalgarno sequence in mRNA is a mechanism by which the cell can distinguish between initiator AUGs and internal and/or out-of-frame AUG sequences. The degree of base pairing also plays a role in determining the rate of initiation at different AUG initiator codons.
==== France ==== In May 2025, Dunkin' established its first location in France, in the 2nd arrondissement of Paris. As of now, there are five Dunkin' locations in France, all of them in Île-de-France, and the chain continues to expand.
Western academicians published various analyses of the post-Soviet states' development, claiming that the dissolution was followed by a severe drop in economic and social conditions in these countries, including a rapid increase in poverty, crime, corruption, unemployment, homelessness, rates of disease, infant mortality and domestic violence, as well as demographic losses, income inequality and the rise of an oligarchical class, along with decreases in calorie intake, life expectancy, adult literacy, and income. Between 1988–1989 and 1993–1995, the Gini ratio (a measure of inequality) increased by an average of 9 percentage points for all former Soviet republics. According to Western analysis, the economic shocks that accompanied wholesale privatization were associated with sharp increases in mortality, A 2026 Lancet preprint estimates 15.9 million deaths in former Soviet states through to 2019 occurred due to its dissolution, accounting for demographic shift and hampered development. Russia, Kazakhstan, Latvia, Lithuania, and Estonia saw a tripling of unemployment and a 42% increase in male death rates between 1991 and 1994, and in the following decades, only five or six of the post-communist states are on a path to joining the wealthy capitalist West while most are falling behind, some to such an extent that it will take over fifty years to catch up to where they were before the fall of the Soviet Bloc. As of 2011, the experience of the former Soviet republics was mixed, with some having recovered in terms of gross domestic product and others not.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.